2023-12-31-accounts

ݸ¿®·¬§ ²«³¾»®æ ïïêêçèë

ÌØÛ Ô×ÊÛÎ ÙÎÑËÐ ÝØßÎ×ÌÇ Ý×Ñ

ËÒßËÜ×ÌÛÜ ßÒÒËßÔ ÎÛÐÑÎÌ ßÒÜ ßÝÝÑËÒÌÍ

ÇÛßÎ ÛÒÜÛÜ íï ÜÛÝÛÓÞÛÎ îðîí

ÔËÞÞÑÝÕ Ú×ÒÛ ÔÔРݸ¿®¬»®»¼ ß½½±«²¬¿²¬­ כּ®²±­¬»® ر«­» êë ͬ п«´ù­ ݸ«®½¸§¿®¼ Ô±²¼±² ÛÝìÓ èßÞ

THE LIVER GROUP CHARITY CIO CONTENTS Page Reference and Administrative Details of the Charity. its Trustees and Advisers Trustees. Report Chalrman's Statement Independent Examiner's Report Statement of Financial Activities Balance Sheet Notes to the Financial Statements 10-17 The following pages do not form part of the statutory financial stslements.. Donations to the 'Liver for Life. appeal 18 Scientific publications and presentations 19

THE LIVER GROUP CHARITY CIO REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY. ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2023 Trustees Dr David Holbrook Ichairmanl Mary Collier Susan Eggleton Dr Martin Giles Professor Clare Selden Charity registered number 1166985 Principal office CIO Institute for Liver and Digestive Health Royal Free Hospital Campus - University College Medical School Rowland Hill Street Hampslead NW3 2PF Patrons Prof Sir Roger Penrose OM FRS Kay Glendinning MBE Accountsnts Lubbock Fine LLP Chartered Acwunlants & Statutory Auditors Paternoster House 65 St Paul's Churchyar London EC4M 8AB Page 1

THE LIVER GROUP CHARITY CIO TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 The Trustees present the annual report together with the financial statements of The Liver Group Charity CIO for the year ended 31 December 2023. The Trustees confirm that the Annual Report and financial statements of the Charity comply with the current slatulory requirements, the requirements of the Charity's governing document and provisions of the Statement of Recommended Practice ISORPI, applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191. Reference and administrative details The Liver Group Charity CIO I'the Charity l is regISte￿d with the Charity Commission of England and Wales, under registration number 1166985. The Charity was registered on 6 May 2016 as a Charitable Incorporated Organisalion, and as al 30 September 2016 took over the activities and assets of The Liver Group (registered charity number 10245331 which has subsequently been closed. The principal operab'ng address is UCL Institute for Liver and Digestive Health, UCL - Royal Free Hospital Campus, University College Medical School, Upper Third Floor, Rowland Hill Sl, Hampslead, London NW3 2PF. The Trustees who served in the year (including post year end appointments I resignations) were.. Dr David Holbrook Ichaimianl Mary Collier Susan Eggleton Dr Martin Giles Kay Glendinning MBE (resigned on 25 July 20241 Prof Clare Selden Prof Sir Roger Penrose OM FRS Patron Kay Glendinning MBE Patron from 25 July 2024 Structure. governanco and managgmgnt The Board of Management comprised of six Trustees and one Patron during the year ended 31 December 2023. The members are able lo draw on relevant board experience In board deliberations. The Board is collectively responsible for the compelenl management of the organisation in accordance with its objectives which are sel out in the Trust Deed which is the Charity's governing document. The Board meets twice a year lo monitor the organisation's strategy and activities. If the need arose to appoint a new trustee the remaining Trustees would identify and appoint an appropriate person. The current Trustees are responsible for the induction of any new trustee which involves making them aware of the Trustees, responsibilities, the goveming documents, administrative procedures and the history and philosophical approach of the Charity- The Charity does not have any employees and its day to day activities and fundraising efforts are carried out by searchers from University College London, volunteers and trLJStees, under the supervision of one of the Trustees. The Trustees have agreed a position that should any profits arise from the intellectual property in the search being carried out by the team generally, and in conjunction with the various other parties involved in that work, the Charity would be entitled lo a proportion of such amounts as per the Association of Medical Research Documentation IAMRCI. Page 2

THE LIVER GROUP CHARITY CIO TRUSTEES. REPORT {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Objectives and activities The objects of the charity are". 1. The relief of patients suffering from disease of the liver and genetic defects affecting the liver. 2. The promotion of research into the causes and t￿atment of diseases of the liver on terms that the results of such research are published. 3. Without p￿jUdice to the generality of the foregoing to fund and support existing and future research into such matters at UCL Medical School (Liver Group) al the Royal Free Hospital or any other establishment into which such unil may be amalgamated and transferred in the future. The principal activity of the Charity currenuy is the project being conducted to develop an artificial liver. The artificial liver project is being carried out with the funds raised for the continuing 'Liver for Life" Appeal. All the activities of the Charity were undertaken lo further its purposes for the public benefit in line with the Charity's long-lerm objective of providing the relief of patients suffering from diseases of the liver and genetic defects affecting the liver, and promoting research into the causes and treatment of liver disease. The Charity has complied with section 17 of the Charities Act 2011 having due regard of the public benefit guidance published by the Commission. Review of the period {including financial review) The organisalion remains funded mainly by donations. They are a mixture of individual, corporate and charitable trust donations. During the year external donations lotalled £11,45412022.' £40,639). The majority of funds are spent on paying the cost of researchers, as well as the required consumables and equipment for the research lo continue. As evidenced by the publications arising from the work, the Charity's current aim lo develop a bio-artificial liver machine has moved forward from the medium scale to human scale, and now on lo clinical scale, and towards readiness for a firsl-in-human trial. The following period will see an advance to GMP manufacture, regulatory and ethics approval for a first in human trial. Each of these steps is associated with a considerable increase in research personnel, consumable and equipment expenditure. For 2023, expenditure lolalled £173, 189 12022.. £188,537). Except for such funds as the TrLJStees consider prudent lo maintain for the purpose of management and administration of the Charity for the foreseeable future, all unrestricted funds are applied for the purposes of the 'Liver for Life" project and the general charitable objects of the Charity- The Trustees consider that £45,971 12022". £198,501) of unreslricled reserves is more than sufficient lo fund 6 months of current operations. DLJring the period, the Charity recorded a deficit of £154,179 12022.. deficit of £142,8551- The Charity's unrestricted fund is already commilled to existing research. As the bio-artificial liver project nears clinical scale and development for clinical trial, the costs are rapidly increasing neces5ilating considerable further fund-raising. During 2017, the Trustees, on behalf of The Liver Group Charity CIO, entered into an agreement with Liver Health such that a proportion of any income from the sale of their drink product will be donated to The Liver Group Charity CIO. The Trustees felt that this would be a beneficial outcome for the charity if the product is Suc￿sSfUl. As well as proving a financial benefit, it would also raise awareness of the Charity itself and the risks of liver disease. This ag￿ement is ongoing, although no funds have been received in 2022 or 2023. Page 3

THE LIVER GROUP CHARITY CIO TRUSTEES. REPORT {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Achievements and performance Research oulpul, intellectual property gained from the academic group funded by The Liver Group Charity, and achievement of milestones towards moving the bioartificial liver project from the bench to the bedside. Further detsils are sel out in the Chaimian's report on page 6. Administrative charitable activities are limited to fundraising for the research endeavour. This is achieved by written applications to known grant giving organisations, small and large companies via the CEOS or other appropriate individual or wealthy individual donors. The Charity also has a web page with an opportunity lo donate via Chsrities Aid Foundation. During the period from 1 January 2023 10 31 December 2023, external income of £11,454 12022.. £40,639) was raised from donations and grants., other income of £7,556 12022.. £5,043) was generated from interest earned on cash deposits. Indicators of achievements are Suc￿sS in the research aims and, in addition, the total fvnds raised in a particular year. These rarely exceed our expenditure for the year. The Charity is one of many sourcing the same research funding,. given the diffi'cult position most UK universities find themselves in, there is increasing competition for funds. Until government resources fill the gap be￿een the costs and current funding of medical research the Charity's efforts will become more difficult each year. NO￿lthStandIng this difficult climate, and the re￿nt world events having a considerable negative effect on possible fundraising activities the Charity continues to explore every avenue to increase funding from grants and donations. The impact of the Pandemic even in 2023.. The Pandemic has indeed thrown LJP several challenges, both direct to the Charity in terms of making fundraising a lol more difficult, since we were still unable to hold any actual in person fundraising events in areas where likety donations would be forthcoming e.g. hospital foyers etc., nor had volunteers lo organise sponsorship opportunities. We continue our strategy of approaching small trusts by mail with reasonable Suc￿ss, and our social media pages are also a source of fundraising, however, the income in 2023 was considerabty less than the expenditure in that year, and judging by the current situation will not be significantly different in 2024. This has precluded the Charity from providing a PhD sludentship for any new student as the existing sludenl finished in eady 2022. Whilst the research funded by the Charity has returned to practical endeavour in the laboratory, the opportunity to fund fewer researchers is limiting. It has, however, continued as best as possible, with much analysis, input to regulatory documenlab'on and small scale experimental work. Going concern After making appropriate enquiries, the trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial slatemenls. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies. Risk management The Trustees confirm that there are ongoing processes for identifying, evaluating and managing significant risks faced by the organisation. Plans for futurg Pgriods The Charity aims to continue its medical research goals, al a pace commensurate with funding opportunities. With appropriate funding, it sees the biwrtificial liver machine project reach the Clinical trial assessment within five years. Page 4

THE LIVER GROUP CHARITY CIO TRUSTEES. REPORT {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Statement of Trustees, responsibilities The Tmslees are responsible for preparing the Trustees, Report and the financial statement in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable lo charities in England & Wales reqUI￿S the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming sources and application of ￿soUrceS of the charity for that period. In preparing these fi'nancial stslemenls, the Trustees are required lo". select suitable accounting policies and then apply them consislenily., observe the methods and principles in the Charities SORP., make judgements and estimates that are reasonable and prudent", slate whether applicable accounting stsndards have been followed, subject to any Material departures disclosed and explained in the financial slalemenls., prepare the financial statements on the going concern basis unless il is inappropriate to presume that the Charity will continue in operation. The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any lime the financial position of the charity and to enable them to ensure that the financial slalements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and taking reasonable steps for the prevention and detection of fraud and other irregularities. The Trustees are responsible for the Maintenan￿ and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ trom legislation in other jurisdictions. This report was approved by the Trustees and signed on their behalf by.. Dr Martin Giles (Trusteel Dale". 24 Octobe r 2024 Page 5

THE LIVER GROUP CHARITY CIO CHAIRMAN'S STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 The chairman presents his statement for the Year. Despite another difficult fundraising environment for both the charity and the research sectors it has been another year of significant progress for the project which the Charity funds. Professor Clare Selden and her team al University College London IUCLI have continued lo advance the Hepatican TM Project. A noteworthy achievement was re￿Iving the endorsement of the Cell and Gene Therapy Catapult ICGTCI through a £50,000 Commercialisalion of Research Award, which involved significant levels of due diligence and peer review, as well as endorsement of the commercial potential for the projecL Furthermore, the CGTC has agreed to help find further investors for the project. On the technical front, the workstation is now complete and despite some initial electronic glitches has now achieved 1000/0 success on its regulatory tests lo date. Work conlinLJes on cell recovery rates after cryopreservation, with current progress sufficient for patient treatment. The same is true of stability and sterility studies. The team under Professor Selden should be congratulated on this progress over the year. Looking ahead, the Charity is committed to helping in the translation of liver research to the patient, and its primary and sole focus at present las peer reviewed) is to continue to support the artificial liver project at UCL. As the project morphs from a research project lo a development one this changes the landscape of available sources of funding for the project, from academic grants and charitable donab'ons lo more commercial sources such as venture capital and other forms of investment which seeks a financial return. Accordingly, Professor Selden has given noliee to the Charity that she now owns the inlelleelual property relating to the project by way of an assignment agreement with UCL Business and a new palenl in her name 8nd intends lo commercialise Hepatican TM through a company vehicle. Negotiations will take place at arm's length with Professor Selden to ensure that the Charity receives a fair apportionment of any commercial upside which could possibly ensue from the commercialisalion of the intellectual property which the Charity- along with other bodies- has helped to fund. This could, inter alia, include the Charity receiving future payments on the achievement of agreed commercial milestones, royalties, and potentially an equity stske in the company itself. I shall report on progress on this matter in my next Chairman's Statement. In all these mallers the Trustees are mindful to manage any possible conflicts of interest be￿een Professor Selden in her capacity as an academic receiving funding from the Charity, a founder of a spin-out company established to commercialise Hepalican Thl for patient Irealmenl, and as a Trustee of the Charity. The Trustees have, and will continue lo seek, the advice of the Charity Commission on these issues and have adopted the broad Conflict of Interests policy of the British Heart Foundation as an example of best practi￿. Special thanks are due lo all the volunteers, fundraisers, Trustees and scientifi'c researchers and support staff who make this Charity possible. This year, special thanks are due lo the research team of Eloy Erro, Tom Brookshaw and Sherri Chalmers and our completed apprentice Rosa French who we wish well for the future. The board of Trustees have as ever been a great help and special thanks go lo Dr. Martin Giles for his work on financial and risk management matters, Mary Collier on legal issues, and Sue Eggleton for her accounting expertise. Dr David Holbrook Chairman Dale.. 24 October 2024 Page 6

THE LIVER GROUP CHARITY CIO INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 Independent Examiner's Report to the Trustees of The Liver Group Charity CIO I'the Charity.) I report to the charity Trustees on my examination of the accounts of the Charity for the Year ended 31 December 2023. Responsibilities and Basis of Report As the Trustees of the Charity you are responsible for the preparation of the accounts in accordan￿ with the requirements of the Charities Act 2011 I'lhe 2011 Act'i. I report in respect of my examination of the Charitys accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 14515llbl of the 2011 Act. Independent Examiner's Statement I have completed my examination. I confirm that no material matters have eome lo my attention in connection with the examination giving me eause to believe that in any material respect". accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act," or the accounts do not accord with those records,. or the accounts do not comply with the applicable ￿quirementS concerning the form and eonlent of accounts set out in the Charities IAccounts and Reportsl Regulations 2008 other than any requirement that the accounts give a 'lrue and fair, view which is not a matter considered as part of an independent examination. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts lo be reached. This report is made solely lo the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reportsl Regulations 2008. My work has been undertaken so that I might slate lo the Charity's Trustees those matters l am required lo stale to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustee5 as a body, for my work or for this report. PA¥41 Hazra Patel. ACA Lubboek Fine LLP Chartered Accounlanls & Slatulory Auditors Palernosler House 65 St Paul's Churchyard London EC4M 8AB Dale..25 october 2024 Page 7

THE LIVER GROUP CHARITY CIO STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023 Unrestricted funds 2023 Restricted funds 2023 Total funds 2023 Total funds 2022 Note Income from.. Donations and legacies Investments 1,454 7,556 10,000 11,454 7,556 40,639 5,043 Total income 9,010 10,000 19,010 45,682 Exponditure on.. Charitable activities 161,540 11,649 173,189 188,537 Total expenditure 161,540 11,649 173,189 188,537 Net movement in funds 1152,5301 11,6491 1154,1791 1142,8551 Reconciliation of funds: Total funds brought forward Nel movement in funds 198,501 1152,5301 10,000 11,6491 208,501 1154,1791 351,356 1142,8551 Total fvnds Carried forward 45,971 8,351 54,322 208,501 The Statement of Financial Activities includes all gains and losses recognised in the Year. The notes on pages 10 to 17 form part of these financial statements. Page 8

THE LIVER GROUP CHARITY CIO BALANCE SHEET AS AT 31 DECEMBER 2023 2023 2023 2022 2022 Note Current assets Debtors Cash at bank and in hand 7,002 168,606 7,485 295,388 175,608 302,873 Creditors". amounts falling due within one year 1121,2861 194,3721 Net current assets 54,322 208,501 Total net assets 54,322 208,501 Charity funds Reslricled funds Unreslricled funds 8,351 45,971 10,000 198,501 Total funds 54,322 208,501 The fuures shown in brackets above represent amounts paygble by the Charity 8s at 31 December. The financial ststements were approved and authorised for issue by the Trustees and signed on their behalf by". D IV-Y- Or Davld Holbrook Chairman Dale.. 24 October 2024 The notes on pages 10 to 17 form part of these financial statements. Page 9

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Accounting policies 1.1 Basis of preparation of financial statements The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise staled in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice.. Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 and Financial ReFlOrting Standard applicable in the United Kingdom and Republic of Ireland IFRS 1021 effective 1 January 2019 and Charities Act 2011. The Liver Group Charity CIO meets the defi'nition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise ststed in the relevant accounting policy. 1.2 Going concern The charity is mainly reliant upon donations lo raise revenue to meet future expenditure. The Trustees consider that il is appropriate to prepare the fi'nancial statements on a going concern basis due to the level of reseNes held. This also assumes that the charity will be successful in its fundraising aclivilies. The financial statements do not include any adjustments that would result if insufficient funds are raised. 1.3 Income All income is recognised once the Charity has entillemenl lo the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Income tax recoverable in relation to investment income is recognised at the lime the investment income is receivable. 1.4 Expenditure Expenditure is recognised once there is a legal or Constructive obligation lo transfer economic benefit to a third paty, Il is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is Classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, Including support costs Involved in undertaking each activity. Direct costs attributable lo a single activity are allocated directly lo that aclivily. Shared costs which contribute to more than one activity and support costs which are not attributable lo a single activity are apportioned be￿een those activities on a basis consistent with the use of resources. Charitable activity costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity- Expenditure on charitable activities is inCUr￿d on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs. All expenditu￿ is inclusive of ir￿cOVer8b1e VAT. Page 10

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Accounting policies (continued) 1.5 Interest receivable Interest on funds held on deposit is included when r￿1Vable and the amount can be measured reliably by the Charity,. this is normally upon notification of the interest paid or payable by the Bank. 1.6 Debtors Trade and other debtors are recognised al the selllement amount after any trade discount offered. 1.7 Cash at bank and in hand Cash al bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisib'on or opening of the deposit or similar aceounl. 1.8 Liabilities and provisions Liabilities are recognised when there is an obligation at the Balance Sheet dale as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be eslimaled reliably. Liabilities are recognised at the amount that the company anticipates it will pay lo settle the debt or the amount il has received as advanced payments for the goods or services it must provide. Provisions are measured al the best estimate of the 8mounts required lo setue the obligation. Trade and other creditors are ￿CognISed al the settlement amount after any trade discounts received. Accruals are value based on the estimated amount to be paid. 1.9 Flnanclal Instruments The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their selllemenl value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method. 1.10 Fund accounting General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes. Reslricled funds are funds which are to be used in accordan￿ with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each reslricled fund is sel out in the notes to the financial statements. 1.11 Donated goods and servicos The Charity does not value donated services in the accounts. servI￿s that are received, such as volunteers, time and the use of the laboratory Spa￿ at University College London are either deemed not lo be material or too onerous to value for a charity of this size. Page 11

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Income from donations and legacies Unrestricted Restricted funds funds 2023 2023 Total funds 2023 Donations 1,454 10,000 11,454 Unrestricted Restricted funds funds 2022 2022 Total funds 2022 Donations 30,639 10,000 40,639 Investment income Unrestricted funds 2023 Total funds 2023 Bank Interest 7,556 7,556 Unrestricted funds 2022 Total funds 2022 Bank Interest 5,043 5,043 Analysis of expenditure on charitable activities Summary by fund type Unrestricted Restricted funds funds 2023 2023 Total 2023 Charitable costs 161,540 11,649 173,189 Page 12

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Analysis of expenditure on charitable activities (continued) Summary by fund type Icontinuedl Unrestricted funds 2022 Total 2022 Charitable costs 188,537 188,537 Analysls of expendlture by actlvltles Aetlvltles undertaken directly 2023 Support costs 2023 Total funds 2023 Charitable costs 168,674 4,515 173,189 Activities undertaken directly 2022 Support costs 2022 Total funds 2022 Charitable costs 185,346 3,191 188,537 Page 13

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Analysis of expenditure by activities (continued) Analysis of direct costs Total funds 2023 Activities 2023 Palenl costs 11,649 157,025 11,649 157,025 Researchers (costs paid lo UCLI 168,674 168,674 Total funds 2022 Activities 2022 Researchers (costs paid lo UCLI 185,346 185,346 Analysis of support costs Totsl funds 2023 Activities 2023 Accountancy fee Sundry expenses Independent examination fees {governancel Bank charges 2,900 36 2,900 36 1,000 579 1,000 579 4,515 4,515 Total funds 2022 Activities 2022 Accountancy fee Independent examination fees Igovernancel Bank charges 1,650 750 791 1,650 750 791 3,191 3,191 Page 14

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 staff costs The Charity had no employees during the period but supported the costs of researchers who are themselves employed by University College London. The average monthly number of UCL employees supported by The Liver Group Charity CIO during the period was 4. At the period*nd there were 4 employees of UCL working on The Liver Group Charity CIO fvnded research. During the period, a number of volunteers gave their time lo assist the Charity. No remuneration, other than travel expenses lo and from the place of work, were paid to them and the Charity thanks them for their generosity. The Trustees did not receive any renumeration, benefits in kind and reimbursement of expenses 12022". Debtors 2023 2022 Due within one year Other debtors Accrued income 48 6,954 7,485 7,002 7,485 Creditors.. Amounts falling due within one year 2023 2022 Amounts due to UCL Accruals 118,286 3,000 92,272 2,100 121,286 94,372 Page 15

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Statement of funds Statement of funds- current Year Balance at 31 December 2023 Balance at 1 January 2023 Income Expenditure Unrestricted funds General Funds 198,501 9,010 1161,5401 45.971 Restricted funds Palenl costs 10,000 10,000 111,6491 8,351 Total of funds 208,501 19,010 1173, 1891 54,322 The restricted fund was contributed to be used lo cover palenl costs. Statement of funds - prior Year Balance at 31 December 2022 Balance at 1 January 2022 Income Expenditure Unrestricted funds General Funds 351,356 35,682 1188,5371 198,501 Restricted funds Palenl costs 10,000 10,000 Total of funds 351,356 45,682 1188,5371 208,501 Page 16

THE LIVER GROUP CHARITY CIO NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 10. Analysis of net assets between funds Analysis of net assets between funds - current year Unrestricted Restricted funds funds 2023 2023 Total funds 2023 Current assets Creditors due within one year 167,257 1121,2861 8,351 175,608 1121,2861 Total 45,971 8,351 54,322 Analysis of net assets between funds - prior year Unrestricted Restricted funds funds 2022 2022 Total funds 2022 Current assets Creditors due within one year 292,873 194,3721 10,000 302,873 194,3721 Total 198,501 10,000 208,501 11. Related party transactions Donations from trustees lotalled £10,00012022 - £10,000) during the year. At the year end, an amount of £48 was due from a Iruslee12022 - £nill. There were no other related party transactions during the current year or prior year. Page 17

We would also like to thank those who have donated anonymously.

The Liver Group Charity CIO Publications arising from the work funded by the Liver Group Charity in 2023 Microplastlcs and nanoplastics in haemodialysis waters: Emerging threats to be in our radar Passos, RS- Davenport, A- Busquets, R- Selden, C- Silva, LB,. Baptista, IS,. Barcelo, D,.120231 Environmental Toxicology and Pharmacology , 102 , Article 104253. 10.10161i.etap.2023.104253. Green open access 2. UK Patent filed June 2023 Application reference no. J113931GB- Bioartificial Liver 3. Four papers in preparation for submission 2024 now the patent has been filed